Syndax Pharmaceuticals Gains Buy Rating Boost from Revuforj’s Early Approval and Strategic Launch Plan
Syndax Pharmaceuticals (SNDX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kelly ...
BioPharma Dive4h
Syndax secures FDA OK for new kind of leukemia drug
Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...
FiercePharma7h
Syndax ⁠scores FDA approval for Revuforj after it disappointed in another acute leukemia indication
The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...
STAT7h
Pharmalittle: We’re reading about RFK Jr. and vaccines, obesity-drug prescribing for kids, and more
Robert F. Kennedy Jr. would have broad power as HHS secretary to strip vaccine makers' protections against lawsuits ...
Syndax Pharmaceuticals Gains ‘Buy’ Rating Amidst Revuforj’s FDA Approval and Promising Market Prospects
Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Syndax Pharmaceuticals (SNDX – Research Report). The associated ...
Medscape9h
Revumenib Approved for R/R Acute Leukemia With KMT2A Translocation
The US Food and Drug Administration has approved revumenib (Revuforj — Syndax Pharmaceuticals) for relapsed or refractory ...
FDA approves Syndax’s Revuforj to treat leukaemia
The US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating relapsed or ...
STAT22h
Syndax wins U.S. approval for leukemia treatment
The Food and Drug Administration approved on Friday a new drug developed by Syndax Pharmaceuticals to treat patients with a ...